• Miscellaneous diagnostic tests

Spherusol Generic Name & Formulations

General Description

Coccidioides immitis spherule-derived skin test antigen 1.27mcg/0.1mL; soln for intradermal inj; contains phenol.

Pharmacological Class

Antigen test.

How Supplied

Multi-dose vial (1mL)—1

Generic Availability


Spherusol Indications


To detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.

Limitations of Use

Use in patients with unknown exposure to C. immitis is not evaluated. Patients with acute or disseminate coccidioidomycosis, immunodeficiency and history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol.

Spherusol Dosage and Administration


Give by intradermal inj. 18–64yrs: 0.1mL to the volar surface of forearm. Assess for induration at 48±4hrs after administration. Mean induration ≥5mm: positive for delayed-type hypersensitivity response.


<18yrs: not established.

Spherusol Contraindications

Not Applicable

Spherusol Boxed Warnings

Boxed Warning

Larger accelerated reactions may occur. Systemic reactions; may be life-threatening or fatal. Not for IV inj.

Spherusol Warnings/Precautions


Review medical history for skin test sensitivity and related adverse reactions. Have trained personnel and medical equipment readily available. Monitor for ≥30mins post inj for adverse reactions. Immunosuppression. Infection. Elderly. Pregnancy (Cat.C). Nursing mothers.

Spherusol Pharmacokinetics

See Literature

Spherusol Interactions


Concomitant beta-blockers may antagonize epinephrine inj. Concomitant corticosteroids and immunosuppressants may suppress response to the skin test.

Spherusol Adverse Reactions

Adverse Reactions

Itching, swelling, pain; anaphylactic reactions.

Spherusol Clinical Trials

See Literature

Spherusol Note

Not Applicable

Spherusol Patient Counseling

See Literature